Hematologic Oncology

Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.

The combination of the antibody­-drug conjugate loncastuximab tesirine and ibrutinib showed early clinical activity with manageable toxicity in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

The FDA has lifted a partial clinical hold that had been placed on the phase 2 TELLOMAK trial, which is examining the safety and efficacy of lacutamab in patients with advanced T-cell lymphoma.

Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.

John Kuruvilla, MD, FRCPC, discusses the broad utility of pembrolizumab in Hodgkin lymphoma.

Brian T. Hill, MD, PhD, discusses the safety profile of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Findings from an exploratory analysis of the phase 1/2 ZUMA-1 trial demonstrated clinical efficacy in patients with relapsed/refractory large B-cell lymphoma who were retreated with the CAR T-cell therapy axicabtagene ciloleucel.

A supplemental new drug application has been submitted to the FDA for review for the use of ibrutinib in combination with rituximab as a treatment for patients with Waldenström macroglobulinemia.

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for July 14, 2020, to discuss data supporting a biologics license application for belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies.

Brian T. Hill, MD, PhD, discusses the FDA approval of selinexor (Xpovio) in diffuse large B-cell lymphoma (DLBCL).

The FDA has approved selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.

Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

John Kuruvilla, MD, FRCPC, discusses the pivotal KEYNOTE-204 findings in Hodgkin lymphoma and the future of checkpoint inhibitors.

The European Medicines Agency has validated and accepted a marketing authorization application for zanubrutinib for the treatment of patients with Waldenström macroglobulinemia who have received at least 1 prior therapy or as frontline treatment for patients who are ineligible for chemoimmunotherapy.

Ronald Hoffman, MD, discusses the mechanism of action of the investigational hepcidin mimetic PTG-300 in polycythemia vera.

Sarah Rutherford, MD, discusses the importance of including patients with double-hit lymphoma in clinical trials.

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

A new drug application has been completed and submitted to the FDA for the accelerated approval of umbralisib as a treatment for patients with previously treated MZL and follicular lymphoma.